Drug Name Xeljanz (tofacitinib) Drug Class Immunosuppressant Risk minimization type Direct Healthcare Professional Communication DHPC Specialty (Theraputic area) Rheumatology Risk Important Drug Warning - Risk of Major Adverse Cardiovascular Events and Malignancies (Excluding NMSC) with Use of Xeljanz/Xeljanz XR (tofacitinib) Relative to TNFi Therapy Dear Healthcare provider letter DHPC